Feb 10, 2023 / 03:00AM GMT
Operator
Welcome to Aurobindo Pharma Q3 FY '23 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to management for opening remarks. Thank you, and over to you.
Deepti Thakur -
Thank you, Vandit. Good morning, and a warm welcome to our Third Quarter FY '23 Earnings Call. I am Deepti Thakur from the Investor Relations team. We hope you have received the Quarter 3 FY '23 financials and the press release that was sent out yesterday. These are also available on our website.
I would like to introduce my senior management team today on the call with us. Represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines and Peptide Businesses; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; Mr. Sanjeev Dani, COO and Head, Formulations, Aurobindo Pharma Limited; Mr. Swami Iyer, CEO Aurobindo Pharma USA; and Mr. S. Subramanian, CFO.
We will begin the call with summary highlights from the management followed by an interactive Q&A session. Please note that some of the
Q3 2023 Aurobindo Pharma Ltd Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot